Transcript Schmaltz_Discussion_slides_5.10.04

Discussion slides
EU RTD + FP6 - 1 -
Cancer Research in the EU
6th Framework Programme (FP6)
Life sciences, genomics and biotechnology for health
(one of 7 thematic priorities) (2514 Mill. €)
Advanced Genomics and
its Application for Health
Fundamental
Genomics
Biotechnology
for Health
Cancer-related topics
(ca. 140 Mill. EUR)
EU RTD + FP6 - 2 -
Combating Major Diseases
Applicationoriented
genomic
approaches
to
other major
diseases
Combating
Cancer
(ca. 310 Mill. €)
Confronting
povertyrelated
communicable
diseases
Cancer Research in FP6
EU Support

Different Support Schemes: Networks of Excellence (NoE),
Integrated Projects (IP), Specific Targeted Research Projects
(STREP), Specific Support Actions (SSA) etc.

Specific calls for proposals (Topics determined through
Expressions of Interest, Advisory Group, Programme
Committee etc.)

Evaluation and „ranking“ through independent high-level
international expert panel

EU contribution up to > 10 Mill. EUR/project for 3-5 years
EU RTD + FP6 - 3 -
Cancer Research in FP6
Calls

1st call (deadline March 2003): 25 projects funded (for 37 Mill €)
– Examples of topics: “molecular targets for treatments”, “phase
I/II clinical trials”, “molecular imaging”, “networking of cancer
registries and repositories”, “organ-specific metastatic growth
processes in breast cancer”, “mechanisms of cancer-related
pain”

2nd call (currently open, deadline 16 November)
– Examples of topics: “networks for uncommon cancers”,
“prevention of cancer in high-risk populations”, “immune control
of tumours”


EU RTD + FP6 - 4 -
3rd call (2005)
Further information:
http://www.cordis.lu/lifescihealth/cancer/home.htm
A New European Research Strategy
Joint effort by EU and member states to address
structural deficits of European Research
•Fragmentation
•Under-resourcing
•Unfavourable environment for
research and innovation
Establish critical
mass!
↑
R+D to 3% of
GDP!
Strengthen “public-private partnerships!
Promote innovation!
EU RTD + FP6 - 5 -
FP6 (2002-2006)
EUR 17.5 billion
EU RTD + FP6 - 6 -
Budgets of the EU
Framework Programmes
20
EUR billion
17.5
18
14.96
16
13.12
14
12
10
8
5.36
6
4
6.6
3.27
2
0
1984-1987
FP1
1987-1991
FP2
1990-1994
FP3
1994-1998
FP4
1998-2002
FP5
2002-2006
FP6
(Comparison: Annual Budget U.S. National Institutes of Health (only Health Sciences): 27 Bill. $)
EU RTD + FP6 - 7 -
The EU’s budget 2002
CAP
Structural Funds
RTD
Administration
Other
Total value of commitments:
EUR 98.6 billion
45.1%
34.5%
11.0%
EU RTD + FP6 - 8 -
5.2%
4.1%
Topics for the 1st call
Combating Cancer
2.2.0-1
Translating basic knowledge of functional oncogenomics into cancer
diagnosis and treatment
IP
NoE
17
3
3
2.2.0-2
Multidisciplinary research to explore and validate molecular targets for innovative treatment
IP
35
7
7
2.2.0-3
Networking for treatment and/or prevention clinical trials aimed at
impoving clinical practice in the light of new molecular knowledge
NoE
13
7
2
2.2.0-4
Innovative research in radiation therapy
IP
NoE
10
2
2
2.2.0-5
Molecular Imaging for early detection of tumours and monitoring of treatment
IP
NoE
16
5
3
2.2.0-6
Networking of quality controlled cancer registries and repositories
for molecular epidemiology and quality assessment
NoE
4
1
1
2.2.0-7
Molecular mechanisms involved in organ-specific metastatic growth
processes in breast cancer
STREP
CA
3
2
2
2.2.0-8
Translational research on promising predictive and prognostic markers
STREP
CA
18
5
5
2.2.0-9
Cancer-related pain
STREP
CA
0
0
0
116
32
25
Total
EU RTD + FP6 - 9 -
Evaluation 1st Call Cancer Research in
Priority 1

Balanced coverage of basic-clinical research activities

32 out of 116 proposals (27,5%) above threshold

Combating Cancer: 25 out of 32 proposals (78%)
(14 IP, 4 NoE, 7 STREPs)

Satisfactory participation of SMEs (21 out of 25 projects)

Fundamental/Applied Genomics: 11 proposals
(5 IP, 2 NoE, 4 STREP)

total EU-funding 171 million euro
EU RTD + FP6 - 10 -
EVALUATION 1st CALL COMBATING CANCER

Validation of current innovative oncogenomics technologies (INTACT, TRANSFOG)

Comprehensive coverage of molecular pathways (p53, angiogenesis, proteases, hypoxia, telomerase) ( ACTIVEP53, MUTP53, EUROXY, STROMA,
ANGIOTARGETING, CANCERDEGRADOME, MOL CANCER MED)

A focused effort on breast, leukemia and prostate cancer (PRIMA, P-MARK, DNA-METHYLATION, TRANS-BIG, LEUKEMIANET, BRECOSM,
METABRE)

Web-based brain tumour diagnosis/prognosis (E-TUMOUR)

Improvement of radiotherapy using adult stem cell lines (FIRST)

Promising molecular targets (MCL NETWORK, PROTHETS, ENACT)

A good coverage of molecular imaging technologies, devices and radiotherapy (EMIL, BIOCARE, MAESTRO)

The establishment of harmonised procedures for quality controlled bio-banks for basic and clinical research (CCPRB)
• A good coverage of molecular imaging technologies,
devices and radiotherapy (EMIL, BIOCARE, MAESTRO)
EU RTD + FP6 - 11 -
EVALUATION 1st CALL
BASIC AND APPLIED ONCOGENOMICS/
BIOTECHNOLOGY FOR HEALTH

Optimised delivery systems and technologies for vaccination (THERAVAC, ALLOSTEM, DC-VACC,
GENOMES TO VACCINES, DENDRITOPHAGES)

Disease models (ZF-MODELS, FUNGENES)

Basic and applied Genomics (LYMPHANGIOGENOMICS, MITOCHECK, THE EPIGENOME)
EU RTD + FP6 - 12 -
Overview 3rd call
Cancer
Budget: ± 95 Million Euro
3 IP / 2 NoE
75 %
EU RTD + FP6 - 13 -
3 STREPS 1 SSA/CA
25 %
2.2
Topics 3rd call
Cancer
Research into immune control of tumours for prevention
and therapy
IP
Relevant models for pre-clinical tests and evaluation of
new therapies
IP
Research on tumours associated with infectious agents
IP
Development of European networks to promote research
into uncommon cancers in adults and children
NoE
Prevention of cancer in high risk populations
NoE
EU RTD + FP6 - 14 -
Topics 3rd call
Cancer
2.2
Prevention, detection and treatment of familial cancers, such
as cancer of the prostate, ovary, breast, colon and skin
STREP
Molecular-oriented detection and treatment of minimal
disease
STREP
Tumour-host interactions
STREP
Feasibility study for the coordination of national cancer
research activities*
*Deadline 9 Sept !
EU RTD + FP6 - 15 -
SSA/
CA
Topics 3rd call
1.1 1.2
BASIC AND APPLIED ONCOGENOMICS/
BIOTECHNOLOGY FOR HEALTH
New Screening techniques and strategies in the early diagnosis of
solid tumors
Overcoming the limitations of stem cell therapy for solid tumours
Highly sensitive tests for the assessment of haematological
malignancies
IP
IP
STREP
Development of new non-viral gene delivery technologies for ex vivo
gene-based therapies
STREP
Exploring the potential of human umbilical cord blood stem cells for
application other than allogeneic haematopoietic transplantations
STREP
Oncolytic virus vectors for cancer virotherapy (especially oriented
towards involvement of SMEs)
STREP
EU RTD + FP6 - 16 -
Total R+D
expenditure
Total expenditure on R+D (in % of GDP)
3.2
Japan: 3.0
3.0
2.8
USA: 2.7
2.6
2.4
2.2
EU-15: 1.9
2.0
EU RTD + FP6 - 17 -
20
00
19
99
19
98
19
97
19
96
19
95
19
94
19
93
19
92
19
91
19
90
19
89
19
88
1.8
Source: HM Treasury
EU RTD + FP6 - 18 -
Public funding for health
research
Distribution of GBAORD by socio-economic objective in % 2002
GBAORD = Government buget appropiation or outlays on R+D; GUF = general university funds
EU RTD + FP6 - 19 -
Source: EUROSTAT
Health expenses EU
Source: OECD
Health Data
2003
EU RTD + FP6 - 20 -
What research for health?
The “health research value chain”:
 Basic research
 Translational research
 Clinical research
 Outcomes research
 Health systems research
EU RTD + FP6 - 21 -
A New European Research Strategy
Joint effort by EU and member states to address
structural deficits of European Research
•Fragmentation
•Under-resourcing
•Unfavourable environment for
research and innovation
Establish critical
mass!
↑
R+D to 3% of
GDP!
Strengthen “public-private partnerships!
Promote innovation!
EU RTD + FP6 - 22 -
Total R+D
expenditure
Total expenditure on R+D (in % of GDP)
3.2
Japan: 3.0
3.0
2.8
USA: 2.7
2.6
2.4
2.2
EU-15: 1.9
2.0
EU RTD + FP6 - 23 -
20
00
19
99
19
98
19
97
19
96
19
95
19
94
19
93
19
92
19
91
19
90
19
89
19
88
1.8
Source: HM Treasury
EU RTD + FP6 - 24 -
Public funding for health
research
Distribution of GBAORD by socio-economic objective in % 2002
GBAORD = Government buget appropiation or outlays on R+D; GUF = general university funds
EU RTD + FP6 - 25 -
Source: EUROSTAT
Health expenses EU
Source: OECD
Health Data
2003
EU RTD + FP6 - 26 -
What research for health?
The “health research value chain”:
 Basic research
 Translational research
 Clinical research
 Outcomes research
 Health systems research
EU RTD + FP6 - 27 -
Need for Clinical Trials
EU RTD + FP6 - 28 -

Only mean to validate in the clinical context the effectiveness of new drugs
or other treatments, procedures, preventive approaches, etc

Normally performed by industry, but influenced by market possibilities

Lack of investment on drugs for orphan diseases (small n° of patients),
vaccines, poverty-related diseases, non-patent protected drugs, non-drug
treatments (surgery, radiation, etc), non-profit academic clinical trials

Difficulties with EU Pharmaceutical legislation (EU Directive for clinical trials)
Impact of research – potential for
cost savings
EU RTD + FP6 - 29 -
Impact of research – potential for
Introduction of HAART
cost savings
(highly active antiretroviral treatment)
N Engl J Med 2001;344:817-23
EU RTD + FP6 - 30 -
Clinical research (costs)
Lancet, 2002
EU RTD + FP6 - 31 -
A New European Research Strategy
Joint effort by EU and member states to address
structural deficits of European Research
•Fragmentation
•Under-resourcing
•Unfavourable environment for
research and innovation
Establish critical
mass!
↑
R+D to 3% of
GDP!
Strengthen “public-private partnerships!
Promote innovation!
EU RTD + FP6 - 32 -
Total R+D
expenditure
Total expenditure on R+D (in % of GDP)
3.2
Japan: 3.0
3.0
2.8
USA: 2.7
2.6
2.4
2.2
EU-15: 1.9
2.0
EU RTD + FP6 - 33 -
20
00
19
99
19
98
19
97
19
96
19
95
19
94
19
93
19
92
19
91
19
90
19
89
19
88
1.8
Source: HM Treasury
EU RTD + FP6 - 34 -
Public funding for health
research
Distribution of GBAORD by socio-economic objective in % 2002
GBAORD = Government buget appropiation or outlays on R+D; GUF = general university funds
EU RTD + FP6 - 35 -
Source: EUROSTAT
Health expenses EU
Source: OECD
Health Data
2003
EU RTD + FP6 - 36 -
What research for health?
The “health research value chain”:
 Basic research
 Translational research
 Clinical research
 Outcomes research
 Health systems research
EU RTD + FP6 - 37 -
Impact of research – potential for
cost savings
EU RTD + FP6 - 38 -
Impact of research – potential for
Introduction of HAART
cost savings
(highly active antiretroviral treatment)
N Engl J Med 2001;344:817-23
EU RTD + FP6 - 39 -
Clinical research (costs)
Lancet, 2002
EU RTD + FP6 - 40 -
Total public R+D funding
GBAORD = Government buget appropiation
or outlays on R+D
PPS= Purchasing power standards
EU RTD + FP6 - 41 -
Total public R+D funding
EU RTD + FP6 - 42 -
Pharma research
EU RTD + FP6 - 43 -
Pharma research
EU RTD + FP6 - 44 -
Cancer Research in FP6
Example: TRANSBIG

Project Type:
Network of Excellence

Project title:
TRANS-BIG - Translating molecular
knowledge into early breast cancer
management: building on the BIG
network for improved treatment tailoring

Coordinator:
Dr. M. Piccart-Gebhart (Institut Jules
Bordet, Brussels/BE)
Total budget:
EU contribution:
N° of partners:
N° of countries:
24 m €
7m€
39 partners
21 countries




EU RTD + FP6 - 45 -